Drug Topics

JULY 7, 2025

Panelists discuss how pharmacists should ensure patients receive at least one conjugated pneumococcal vaccine (PCV-15, PCV-20, or PCV-21) as the foundation of protection, with subsequent vaccine sequencing depending on which initial vaccine was given—where PCV-15 recipients should receive PPSV-23 one year later for additional serotype coverage, patients (..)

Vaccines 247

Vaccines 247

Drug Topics

JUNE 20, 2025

Experts discuss the recent dismissal of all 17 members of the Advisory Committee on Immunization Practices (ACIP), a panel that provides guidance to the CDC on vaccine recommendations. This abrupt change has raised significant concerns within the health care community about the potential impact on vaccine trust and public health policy.

Vaccines 315

Vaccines Immunization Specialty Pharmacies Compounding 315

Drug Topics

JUNE 30, 2025

Panelists discuss how pneumococcal vaccines differ between conjugated vaccines (PCV-15, PCV-20, PCV-21) and polysaccharide vaccines (PPSV-23) in terms of immune response mechanisms and serotype coverage, with current CDC recommendations now including all adults aged 50 and older for vaccination while maintaining risk-based recommendations for adults (..)

Vaccines 247

Vaccines Immunization 247

Drug Topics

JULY 14, 2025

Panelists discuss how patients who previously completed pneumococcal vaccination with both PCV-13 and PPSV-23 may benefit from additional conjugate vaccine coverage with PCV-20 or PCV-21, with specific timing recommendations based on age and risk factors—including waiting at least 5 years after the last dose for high-risk patients under 50, following (..)

Vaccines 247

Vaccines 247

Drug Topics

JUNE 22, 2025

Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, highlights the critical role pharmacists play in navigating vaccine recommendations and supporting patient understanding.

Vaccines 315

Vaccines 315

Drug Topics

JUNE 21, 2025

Deanna Tran, PharmD, BCACP, FAPhA, emphasizes community outreach, especially in areas with high vaccine hesitancy, as a crucial strategy for maintaining public trust in vaccination programs.

Vaccines 247

Vaccines 247

Drug Topics

JULY 2, 2025

As concerns mount over potential shifts in vaccine recommendations, Deanna Tran, PharmD, BCACP, FAPhA, advocates for rigorous data assessment and patient-centered communication strategies.

Vaccines 315

Vaccines Communication 315

Drug Topics

JULY 7, 2025

Panelists discuss how ACIP's decision to lower the pneumococcal conjugate vaccine age recommendation from 65 to 50 years was supported by evidence showing that 33-54% of adults aged 50-64 already had risk factors for vaccination, nearly 90% of those hospitalized with pneumococcal disease in this age group had at least one risk condition, mortality (..)

Vaccines 247

Vaccines Hospitals 247

Drug Topics

JUNE 6, 2025

Lauren Angelo, PharmD, MBA, associate dean of academic affairs at Rosalind Franklin University of Medicine and Science, highlights significant concerns about the evolving landscape of COVID-19 vaccine policy.

Vaccines 436

Vaccines 436

Drug Topics

JUNE 16, 2025

Researchers wanted to address the potential impact of pharmacist-led influenza immunization services on vaccine uptake in older adults living in Denmark.

Vaccines 341

Vaccines Immunization 341

Drug Topics

JUNE 17, 2025

Researchers conducted a systematic review and meta-analysis to estimate vaccine coverage and identify factors associated with vaccination among forcibly displaced, pediatric populations.

Vaccines 281

Vaccines 281

Pharmacy Times

JULY 17, 2025

The FDA approves a prefilled syringe for the zoster vaccine recombinant, enhancing shingles vaccination convenience and effectiveness for adults 50 and older.

Vaccines 111

Vaccines FDA 111

PharmaVoice

JULY 9, 2025

Today, we’re speaking to Simone Steiner, Transgene’s new chief technology officer, about how the company is transitioning from early- to late-stage testing and advancing its manufacturing capabilities Oncology vaccines are gaining traction in the clinic as potential game changing treatments for cancer.

Vaccines 232

Vaccines Immunization 232

Pharmacy Times

JULY 16, 2025

The shift away from thimerosal may increase the use of single-dose syringes, impacting vaccination practices in various healthcare settings. ACIP's recommendations are increasingly significant for pharmacies, influencing vaccination planning, billing, and patient care activities.

Vaccines 100

Vaccines Community Pharmacies Immunization Compounding Pharmacies 100

Pharmacy Times

JULY 17, 2025

An expert discusses how pharmacists can ensure completion of multidose pneumococcal vaccine series through electronic reminder systems, state immunization registries, scheduled follow-up appointments, and providing patients with printed vaccine cards for tracking purposes.

Vaccines 65

Vaccines Immunization 65

STAT

JUNE 26, 2025

A federal vaccine advisory panel, which health secretary Robert F. recently stacked with handpicked members , recommended on Thursday that Americans should not receive flu vaccines containing the preservative thimerosal. Kennedy Jr.

Vaccines 142

Vaccines 142

STAT

JUNE 24, 2025

to remove and replace all members of the government’s independent vaccine advisory committee doesn’t just change how the nation will approach vaccine policy. Kennedy Jr. It could also take money out of Americans’ wallets. Continue to STAT+ to read the full story…

Insurance Coverage 136

Insurance Coverage Insurance Vaccines Immunization 136

STAT

JUNE 23, 2025

WASHINGTON — A key Senate health leader is calling for this week’s meeting of the panel of vaccine advisers handpicked by Health and Human Services Secretary Robert F. to be delayed, citing their lack of experience and potential bias against some vaccines. Kennedy Jr. Bill Cassidy (R-La.)   Read the rest…

Vaccines 145

Vaccines Immunization 145

STAT

JUNE 24, 2025

Childhood vaccination coverage has made leaps since 1980. That is according to a study published in The Lancet Tuesday, which found stagnation and wide variation in childhood vaccination rates since 2010. But progress has significantly slowed in the last two decades.

Vaccines 143

Vaccines Immunization 143

Pharmacy Times

JULY 10, 2025

An expert discusses how pharmacists can overcome common vaccination barriers by addressing misconceptions about vaccine necessity, making strong provider recommendations, and educating patients about mild adverse effects while building trust through consistent communication.

Vaccines 65

Vaccines Communication 65

Pharmacy Times

JULY 11, 2025

Panelists discuss that building trust with vaccine-hesitant patients requires pharmacists to slow down, listen empathetically, and ask open-ended questions to understand individual concerns; by addressing specific fears with clear, tailored information and practicing cultural sensitivity, pharmacists can foster ongoing, respectful dialogue that gradually (..)

Vaccines 65

Vaccines 65

Pharmacy Times

JULY 3, 2025

An expert discusses how pharmacists should follow CDC immunization schedules for different age groups and use shared clinical decision-making for patients with prior vaccination history, while considering contraindications primarily related to severe allergic reactions to vaccine components.

Vaccines 65

Vaccines Immunization 65

Pharmacy Times

JULY 11, 2025

Panelists discuss the 3 FDA-approved RSV vaccines for high-risk adults—2 recombinant protein-based (1 adjuvanted, 1 bivalent) and one mRNA-based—highlighting differences in formulation, mechanism, and preparation, and emphasizing the importance of education to address misconceptions and guide appropriate vaccine selection.

Vaccines 65

Vaccines FDA 65

Pharmacy Times

JULY 11, 2025

Panelists discuss recent safety updates on RSV vaccines, including a rare potential risk of Guillain-Barré syndrome (GBS) in older adults receiving recombinant vaccines, emphasizing that benefits outweigh risks and highlighting the pharmacist’s role in educating patients about common adverse effects, recognizing early signs of rare adverse events, (..)

Vaccines 65

Vaccines 65

Pharmacy Times

JUNE 27, 2025

With the Advisory Committee on Immunization Practices recommending that adults receive thimerosal-free influenza vaccines, the preservative that was phased out of most childhood vaccines in 2001 has reentered the public eye.

Vaccines 114

Vaccines Immunization 114

Pharmacy Times

JULY 11, 2025

Panelists discuss how community pharmacies have become trusted hubs for adult vaccinations, with pharmacists not only administering vaccines but also educating patients and coordinating with other health care providers to ensure clear, unified messaging; they emphasize the importance of collaboration, empowering pharmacists to use clinical judgment, (..)

Vaccines 65

Vaccines Community Pharmacies Insurance 65

Pharmacy Times

JULY 11, 2025

Panelists discuss how pharmacists can address patients’ growing vaccine fatigue and misconceptions—such as underestimating RSV’s severity in adults or believing it requires multiple doses—by providing clear, consistent education and emphasizing that a single RSV vaccine offers protection against serious illness in high-risk populations.

Vaccines 65

Vaccines 65

Pharmacy Times

JULY 9, 2025

In a community of older adults, initiating a pneumococcal vaccination support program reduced annual pneumonia-related mortality by 25%, demonstrating broad public and individual health benefits.

Vaccines 73

Vaccines 73

Pharmacy Times

JULY 8, 2025

New research reveals that extracellular vesicles enhance intranasal flu vaccines, boosting mucosal immunity and offering broader protection against diverse strains.

Vaccines 65

Vaccines Immunization 65

Pharmacy Times

JUNE 24, 2025

Six years following vaccination with 23-valent pneumococcal polysaccharide vaccine in a Chinese population, antibody levels remained high, though not as high as 28 days following vaccination.

Vaccines 73

Vaccines 73

Pharmacy Times

JULY 11, 2025

Panelists discuss vaccine hesitancy surrounding the new RSV vaccine, highlighting factors such as uncertainty about safety and effectiveness, cost concerns, limited health literacy, language barriers, and lingering skepticism fueled by the COVID-19 pandemic, emphasizing how pharmacists can address these issues through tailored education, insurance (..)

Vaccines 81

Vaccines Communication Insurance 81

Pharmacy Times

JUNE 20, 2025

Expanding use of the 15-valent pneumococcal conjugate vaccine (PCV15) or 20-valent pneumococcal conjugate vaccine (PCV20) to all United States adults aged 50 to 64 years would result in modest budget increases over a 3-year period. 1,2 A particular disease burden is present for Black Americans.

Vaccines 73

Vaccines Compounding Pharmacies Immunization Hospitals 73

Pharmacy Times

JULY 10, 2025

An expert discusses how pharmacists can evaluate patients with prior adverse vaccine reactions by distinguishing between mild local reactions and serious anaphylactic responses, then recommending supervised vaccination or medical center administration when appropriate.

Vaccines 65

Vaccines 65

Pharmacy Times

JULY 15, 2025

Adam James, PharmD, and Chris Altman, PharmD, discuss renewed public scrutiny of thimerosal, its limited use in vaccines today, and how new guidance may affect pharmacists and patient confidence moving forward.

Vaccines 50

Vaccines 50

Pharmacy Times

JULY 11, 2025

Panelists discuss that pharmacies should prioritize practical workflow and patient management over clinical preference when administering RSV vaccines, since all FDA-approved vaccines are equally recommended; focusing on factors like preparation ease, storage, patient eligibility, and insurance helps streamline operations and promote timely vaccination (..)

Vaccines 65

Vaccines Insurance FDA 65

pharmaphorum

JUNE 26, 2025

Scientists behind a study suggesting GSK's RSV vaccine may be protective against dementia have said the adjuvant used in it may be responsible

Vaccines 93

Vaccines 93

Pharmafile

JULY 15, 2025

French biopharma, Osivax, has announced positive results from its phase 2 study, OVX836-004, into OVX836, its broad-spectrum influenza vaccine lead candidate. The results have been published in the journal, Vaccines.

Vaccines 59

Vaccines 59